欧美自拍另类欧美宗合图片区,国产视频一区二区三区四区,日本一区二区三区四区视频,婬片一区AAA毛片一区二区

商品編號


AG-40T-0382-C500



品牌


Adipogen



公司


Adipogen



公司分類


Proteins



Size

500 ?g

商品信息


More Information



Product Details



Synonyms

Small Ubiquitin-related Modifier 3; HSMT3; SMT3 Homolog 1; Ubiquitin-like Protein SMT3B



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human SUMO3 (Accession Nr. P55854).



Crossreactivity

Human



Formulation

Liquid. In 50mM HEPES pH 8.0, 150mM NaCl, 1mM DTT.



Other Product Data


Use:
Can be conjugated to substrate proteins via the subsequent actions of an SUMO-activating (E1) enzyme, an SUMO-conjugating (E2) enzyme, and an SUMO ligase (E3). Reaction conditions will need to be optimized for each specific application. We recommend an initial protein concentration of 10-50?M.



Declaration

Manufactured by Boston Biochem



Shipping and Handling



Shipping

DRY ICE



Short Term Storage

-20°C



Long Term Storage

-80°C



Handling Advice

Aliquot to avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -80°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Small Ubiquitin-like Modifier 3 (SUMO3), also known as SMT3A, is synthesized as a 103 amino acid (aa), propeptide with a predicted 11.5 kDa. SUMO3 contains a two aa C-terminal prosegment. Human SUMO3 shares 83% sequence identity with mouse SUMO3. SUMO3 also has high aa sequence homology to SUMO2 and SUMO4, 87% and 75%, respectively. SUMO3 shares only 47% sequence identity with SUMO1. SUMOs are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. All SUMO proteins share a conserved ubiquitin domain and a C-terminal diglycine cleavage/attachment site. Following prosegment cleavage, the C-terminal glycine residue of SUMO3 is enzymatically attached to a lysine residue on a target protein. In humans, SUMO3 is conjugated to a variety of molecules in the presence of the SAE1/UBA2 SUMO-activating (E1) enzyme and the UBE2I/Ubc9 SUMO-conjugating (E2) enzyme. In yeast, the SUMO-activating (E1) enzyme is Aos1/Uba2p. Because of the high level of sequence homology most studies report effects of SUMO2/3. For example, addition of SUMO2/3 was shown to modulate the function of ARHGAP21, a RhoGAP protein known to be involved in cell migration. Other reports indicate that the conjugation by SUMO2/3, but not SUMO1, may represent an important mechanism to protect neurons during episodes of cerebral ischemia. However, studies suggest that SUMO2/3 expression is regulated in an isoform-specific manner since oxidative stress downregulated the transcription of SUMO3, but not SUMO2. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1,RANBP2, PML, p53, Sp100, HIPK2) but there are also cytosolic substrates (IκBα, GLUT1,GLUT4). SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation, transcriptional regulation, cancer and protein st
ABI
lity.